|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size 3/28/24 Aspira Women’s Health Inc. 8-K:2,9 3/28/24 11:448K |
Document/Exhibit Description Pages Size 1: 8-K Current Report HTML 73K 2: EX-99.1 Miscellaneous Exhibit HTML 237K 6: R1 Document and Entity Information HTML 48K 8: XML IDEA XML File -- Filing Summary XML 11K 11: XML XBRL Instance -- awh-20240328x8k_htm XML 16K 7: EXCEL IDEA Workbook of Financial Report Info XLSX 8K 4: EX-101.LAB XBRL Labels -- awh-20240328_lab XML 48K 5: EX-101.PRE XBRL Presentations -- awh-20240328_pre XML 34K 3: EX-101.SCH XBRL Schema -- awh-20240328 XSD 11K 9: JSON XBRL Instance as JSON Data -- MetaLinks 12± 18K 10: ZIP XBRL Zipped Folder -- 0000926617-24-000009-xbrl Zip 29K
| awh-20240328x8k |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form i 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): i March 28, 2024
i Aspira Women’s Health Inc.
(Exact name of registrant as specified in its charter)
|
|
|
i Delaware | i 33-0595156 | |
(State or other jurisdiction | (Commission | (IRS Employer |
of incorporation) | File Number) | Identification No.) |
|
|
|
i 12117 Bee Caves Road, i Building III, i Suite 100, i Austin, i Texas |
| i 78738 |
(Address of principal executive offices) |
| (Zip Code) |
Registrant’s telephone number, including area code: ( i 512) i 519-0400
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
i ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
i ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
i ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
i ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
i Common Stock, par value $0.001 per share | i AWH | i Nasdaq Capital Market |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company i ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Conditions.
On March 28, 2024, Aspira Women’s Health Inc. (the “Company”) issued a press release reporting financial results for the three and twelve months ended December 31, 2023. A copy of the Company’s press release is attached hereto as Exhibit 99.1.
The information provided in this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
Exhibit No. | Description |
Press Release issued by Aspira Women’s Health on March 28, 2024 | |
104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
| ASPIRA WOMEN’S HEALTH INC. |
|
|
|
Date: March 28, 2024 | By: | /s/ Torsten Hombeck |
|
| |
|
| Chief Financial Officer |
| This ‘8-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on / For Period end: | 3/28/24 | None on these Dates | ||
| 12/31/23 | ||||
| List all Filings | ||||